Overall response rate of 22% in Phase IIb for CytRx's aldoxorubicin
This article was originally published in Scrip
Executive Summary
CytRx's targeted chemotherapy drug aldoxorubicin generated a response in 22% of soft tissue sarcoma patients treated with the company's targeted chemotherapy drug versus no responses in doxorubicin-treated Phase IIb clinical trial participants, but the rates of stable disease were equal in both arms of the trial.